Merck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use

Post FDA approval, Merck's (MRK) anti-PD-1 therapy Keytruda is now approved as an adjuvant treatment for adult & pediatric patients with stage IIB, IIC or III melanoma following complete resection.